about
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signalingMutant Gq/11 promote uveal melanoma tumorigenesis by activating YAPGermline mutations in BAP1 predispose to melanocytic tumorsNetwork of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genesMetastatic disease from uveal melanoma: treatment options and future prospectsResistant mechanisms to BRAF inhibitors in melanomaRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentAnimal Models of Uveal Melanoma: Methods, Applicability, and LimitationsUveal melanoma as a target for immune-therapyAnimal Eye Models for Uveal MelanomaUveal Melanoma Patient-Derived XenograftsDrosophila as a Potential Model for Ocular TumorsNovel Insights into the Role of Long Noncoding RNA in Ocular DiseasesChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Melanoma: oncogenic drivers and the immune systemUpcoming translational challenges for uveal melanomaSomatic mosaicism in the human genomeRecent developments in prognostic and predictive testing in uveal melanomaThe G protein α chaperone Ric-8 as a potential therapeutic targetMelanoma: new insights and new therapiesAdjuvant Therapy of Uveal Melanoma: Current StatusPathways and therapeutic targets in melanomaEmerging patterns of somatic mutations in cancerResistance to BRAF inhibitors: unraveling mechanisms and future treatment optionsMelanoma: from mutations to medicineMetastatic uveal melanoma: biology and emerging treatmentsImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyWhole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.Clinical application of genetic testing for posterior uveal melanomaMetabolic rewiring in melanomaThe genetics of uveal melanoma: current insightsDisorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasisGenetics of melanocytic neviARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaHippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
P2860
Q24294906-EFAB0E1B-4871-4E2D-B3E1-B34BF549C84DQ24298571-0BB96185-6E60-4816-AF82-A5B69B2DFBDBQ24594891-E6EFDFE1-253C-44FB-BF86-12CA844DCF69Q24619351-24AF1A90-FCF5-4AEA-8272-4E01F680FE87Q26738377-8CC0307C-4F0F-4226-90BB-667B3835509FQ26739717-B22D312C-5BF4-443D-95B1-6D77820C6DD5Q26740631-222246D3-D630-4ECD-94C9-3E0B48542CCFQ26745595-F1E040AF-E18C-466B-A956-7630E6562719Q26747519-F3B29F9F-A459-4CC4-A9BE-8F341E6B2C66Q26750368-FFB750A2-10EE-4116-B34A-3E2A5D0F2710Q26750371-A53784B9-40F9-49BB-AC0A-AD40F75F6052Q26750375-5DF9E72E-7471-49DE-B107-0BC7FBF077A4Q26752617-83B72DB7-FFAA-448A-8BEB-9208A2383441Q26770492-E5BBFBE3-2147-49DF-BB44-D1FEEBB32856Q26775598-52D91743-6F69-4371-B638-D1C8F6557AFFQ26778535-EFF78B91-D506-4B97-9DDD-A8007C561F96Q26823199-7A933B3E-D861-42B0-9F88-76FABCD54023Q26824096-8D414391-F7BF-4C65-ACAD-670FC4032CBDQ26824363-66CB3058-8321-4803-98CB-016A99222FBBQ26853127-9D5E3E96-6A4F-4A53-8088-617C35C32237Q26865325-F059309C-7CC9-4421-ACD6-4E90B8C106C3Q26865736-CDD00D2E-7C0D-416F-9967-93377686F789Q27014126-CF85602D-0C14-4ACE-800B-6C9BD5594263Q27023596-E8C12F25-1C2A-470D-A0EE-C5A4C632EF55Q27024061-FE8E4E97-3689-47E5-B06A-8A2A77A2F549Q27028063-ABB9A72C-95DD-41D1-AFD2-85C869324892Q27334924-2D7577F8-CDB7-4B22-A04B-904D8C9F2CCFQ27851856-88D12885-258D-481C-94D4-5D8C876859D1Q27852482-DFD9D8CA-72E7-4FAC-87E1-A72F6DC0A645Q27852827-B8734714-8A22-4E07-82CB-11EDEEEEFB36Q27853021-5BE7AD09-9D39-4A57-8BCB-A3675F384861Q27853068-77A948E2-475E-4A7C-9DCA-80F9A235B216Q27853217-877841E0-B264-42FB-9CD6-26EC7C1042B2Q28066033-048E20C5-D58D-4BAD-A2A6-ADF6432FD6F1Q28069081-14F9D3CC-B03E-44D8-B0FB-161647F46E73Q28073150-A831C68C-4778-4640-82B0-90E56B16E621Q28078843-29415049-C6B6-43D6-AEA8-7BA83C3965BBQ28085036-6BAE3B99-3AA7-4E0D-A1F4-74680EA7AB8BQ28115305-691AA852-DAD2-49FD-ADEA-4E6B60991390Q28269498-56E691C7-BF63-4ABE-AA0D-D5EA0BF00F4A
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mutations in GNA11 in uveal melanoma
@ast
Mutations in GNA11 in uveal melanoma
@en
Mutations in GNA11 in uveal melanoma
@nl
type
label
Mutations in GNA11 in uveal melanoma
@ast
Mutations in GNA11 in uveal melanoma
@en
Mutations in GNA11 in uveal melanoma
@nl
prefLabel
Mutations in GNA11 in uveal melanoma
@ast
Mutations in GNA11 in uveal melanoma
@en
Mutations in GNA11 in uveal melanoma
@nl
P2093
P2860
P50
P3181
P356
P1476
Mutations in GNA11 in uveal melanoma
@en
P2093
Adriana Heguy
Gail Baimukanova
Gary Green
Joan O'Brien
Klaus Busam
M Mert Sozen
Maria C Garrido
Michelle B Crosby
Nancy Bouvier
Raya Khanin
P2860
P304
P3181
P356
10.1056/NEJMOA1000584
P407
P50
P577
2010-12-02T00:00:00Z